Objective: We sought to evaluate the efficacy and safety of vildagliptin, a new dipeptidyl peptidase-4 inhibitor, added to metformin during 24 weeks of treatment in patients with type 2 diabetes.

This study demonstrates that the DPP-4 inhibitor vildagliptin at doses of 50 or 100 mg daily, when added to metformin monotherapy, results in a clinically significant and dose-related decrease in ...